Proton beam therapy takes aim at rare skull base cancer
NCT ID NCT00496522
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing whether proton beam therapy, a precise form of radiation, can control skull base chondrosarcoma after surgery. Fifteen participants who have had maximal surgical removal of their tumor will receive daily proton treatments for about 7 weeks. The study will track how long it takes for the cancer to come back and monitor side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Proton beam therapy (a type of radiation that uses protons instead of X-rays to target tumors precisely)
- What this could lead to
- If successful, this could show that proton beam therapy is an effective way to control skull base chondrosarcoma and delay or prevent its return after surgery.
- What could go wrong
- This is a small, early-phase trial with only 15 participants, so results may not apply to everyone. The treatment may not prevent recurrence and carries risks from radiation exposure to nearby brain structures.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHONDROSARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a targeted pill stall advanced sarcomas?
- Experimental drug tazemetostat offered to patients with rare, aggressive tumors
- Cancer-Killing virus injected directly into tumors shows promise in Mid-Stage trial
- New drug combo aims to stall bone sarcoma in phase 2 trial
- How do patients feel after Nose-Based brain surgery? new study aims to find out
- New targeted pill takes on Hard-to-Treat cancers with IDH mutations